Journal: Cell reports

Article Title: TGF-β1-mediated intercellular signaling fuels cooperative cellular invasion

doi: 10.1016/j.celrep.2025.115315

Figure Lengend Snippet:

Article Snippet: IL-13RA2/CD213a2 (E7U7B) , Cell Signaling Technology , Cat#85677.

Techniques: Recombinant, Reverse Transcription, Bicinchoninic Acid Protein Assay, Staining, RNA Sequencing

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 2. Periodic acid-Schiff’s (PAS) staining (a–h) and MUC5AC immunohistochemical staining (i–p) of normal human bronchial epithelial cells (NHBECs) incubated at the air–liquid interface with IL-13 (10 ng/mL) (a, b, d, f, g, i, j, l, n, o, q) or vehicle (PBS) (c, e, h, k, m, p) for 14 days in the presence of either an anti-IL-13Ra1 antibody (10 mg/mL) (b, c, j, k), an anti-IL-13Ra2 antibody (2.5 mg/mL) (d, e, l, m), an anti-IgG1 isotype control antibody (10 m g/mL) (f, n) or recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 mg/mL) (g, h, o, p). None of the cells were positive after treatment with IL-13 (10 ng/mL) in the absence of the first antibody (q). White arrowheads show PAS-positive goblet cells (a, d, f). Black arrowheads show MUC5AC-positive cells (i, l, n, o). The goblet cells with secretory granules stained clearly with the PAS staining method. On the other hand, there were also surface cells that did not have any goblet cell granules but were stained with PAS, PAS-positive-but-not-goblet cells. Scale bar = 100 mm.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Staining, Immunohistochemical staining, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 3. Number of periodic acid-Schiff’s (PAS) staining positive cells (a, PAS-positive cells), goblet cells (b), MUC5AC staining positive cells (c, MUC5AC- positive cells) and total cells (d) of normal human bronchial epithelial cells incubated with either IL-13 (10 ng/mL), IL-4 (1 ng/mL) or vehicle (PBS) for 14 days at the air–liquid interface, in the presence of either an anti-IL-13Ra1 antibody (10 mg/mL), an anti-IL-13Ra2 antibody (2.5 mg/mL), an anti-IgG1 isotype control antibody (10 mg/mL) or a recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 0.04, 0.4 or 4 mg/mL). Results are means SEM from five different bronchi. Significant differences from PBS alone are Po0.05, Po0.01 and Po0.001. Significant differences from IL-13 alone are 1Po0.05, 11Po0.01 and 111Po0.001.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Staining, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 4. Periodic acid-Schiff’s (PAS) staining (a, b) and MUC5AC immunohistochemical staining (c–e) of normal human bronchial epithelial cells incubated at the air–liquid interface with IL-4 (1 ng/mL) (a–e) for 14 days in the presence of recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 mg/ mL) (b, d). None of the cells were positive after treatment with IL-13 (10 ng/mL) in the absence of the first antibody (e). White arrowheads show PAS- positive goblet cells (a, b). Black arrowheads show MUC5AC-positive cells (c, d). Scale bar = 100 mm.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Staining, Immunohistochemical staining, Incubation, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 6. (a) and (b) Time course of mRNA expression of MUC5AC (a) and IL-13Ra2 (b) in normal human bronchial epithelial cells cultured with IL-13 (10 ng/mL). The results are the mean SEM from 14 different bronchi. Significant differences from values on day 0 are indicated by Po0.05, Po0.02, Po0.005.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Expressing, Cell Culture

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 5. MUC5AC protein concentrations in the supernatants of normal human bronchial epithelial cell treated with IL-13 (10 ng/mL) or IL-4 (1 ng/mL) in the presence or in the absence of either an anti-IL-13Ra1 antibody (10 mg/mL) or a recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 mg/mL) for 14 days. Data are expressed as percent above control vehicle (PBS). The results are mean SEM from three different bronchi. Significant differences from PBS alone are indicated by Po0.05. Significant differences from IL-13 alone are 1Po0.05.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Recombinant, Control

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 7. (a) and (b) The amount of MUC5AC mRNA expression in normal human bronchial epithelial cells (NHBECs) incubated with IL-13 (10 ng/mL) or vehicle of IL-13 (PBS) in the presence of an anti-IL-13Ra1 antibody (10 mg/mL) (a), an anti-IL-13Ra2 antibody (2.5 mg/mL) (b), an anti-IgG1 isotype control antibody (10 mg/mL) or a vehicle of antibodies (PBS) for 7 days. The results are the mean SEM from five different bronchi. Significant differences from the vehicle of IL-13 (PBS) (control) are Po0.01. Significant differences from IL-13 alone are 1Po0.05. (c) The amount of MUC5AC mRNA expression in NHBECs incubated with IL-13 (10 ng/mL) or a vehicle of IL-13 (PBS) in the presence of recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 0.04, 0.4 or 4 mg/mL) or a vehicle of IL-13Ra2 (PBS) for 7 days. The results are the mean SEM from five different bronchi. Significant differences from the vehicle of IL-13 (PBS) (control) Po0.01. Significant differences from IL-13 alone are indicated by 1Po0.05 and 11Po0.01. (d) The amount of MUC5AC mRNA expression in NHBECs incubated with IL-4 (0.1, 1 or 10 ng/mL) or a vehicle of IL-4 (PBS) in the presence of rsIL-13Ra2 (4 mg/mL) or a vehicle of IL-13Ra2 (PBS) for 7 days. The results are mean SEM from five different bronchi. Significant differences from the vehicle of IL-4 (PBS) (control) are Po0.01 and Po0.05.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Expressing, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 8. Immunohistochemical staining of normal human bronchial epithelial cells (NHBECs) for IL-13Ra2 proteins after exposure to PBS (a, vehicle of IL-13) or IL-13 (10 ng/mL) (b, c) for 14 days in the presence (a, b) or in the absence (c) of the first antibody. Weak staining of IL-13Ra2 protein (white arrowheads) was observed 14 days after adding the vehicle of IL-13 (PBS) (a). In contrast, the potency of IL-13Ra2 protein staining increased in NHBECs 14 days after adding IL-13 (10 ng/mL) (b) with strong staining of IL-13Ra2 protein in some cells (black arrowheads). Arrows shows goblet cells (b, c). Bar = 100 mm.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Immunohistochemical staining, Staining

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 9. (a) Time course of a soluble form of IL-13Ra2 proteins concentrations in the supernatants of normal human bronchial epithelial cells (NHBECs) cells after adding IL-13 (10 ng/mL). The results are mean SEM from four different bronchi. Significant differences from values on day 0 arePo0.05. (b) Time course of IL-13Ra2 proteins in lysates of NHBECs after adding IL-13 (10 ng/mL). The results are the mean SEM from four different bronchi. (c) A Western blot analysis of IL-13Ra2 protein in the culture supernatants (lane 1–4) and the cell lysates (lane 6) of NHBECs incubated with IL-13 (10 ng/mL) for 21 days. Lanes shows samples before (day 0, lane 1), and 7 days (day 7, lane 2), 14 days (day 14, lanes 3 and 6) and 21 days (day 21, lane 4) after adding IL-13. The recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 100 ng) is immunoblotted as a positive loading sample (lane 5). The arrow (56 kDa) shows IL-13Ra2. Data are representative of three different experiments.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Western Blot, Incubation, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 10. Western blot analysis of signal transducer and activator of transcription 6 (STAT6) (a) and the phosphorylated, active form of STAT6 (p-STAT6) (b) in the cell lysates of normal human bronchial epithelial cells incubated with IL-13 (10 ng/mL) or IL-4 (1 ng/mL) for 14 days. Lanes show the data from samples treated with either the vehicle of IL-13 or IL-4 (PBS) (lane 1), IL-13 (10 ng/mL) plus the vehicle of antibody (PBS) (lane 2), IL-13 plus anti-IL-13Ra1 antibody (10 mg/mL) (lane 3), IL-13 plus recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 ng/mL) (lane 4), IL-4 (1 ng/mL) plus the vehicle of antibody (PBS) (lane 5) or with IL-4 (1 ng/mL) plus rsIL-13Ra2 (4 ng/mL) (lane 6). The arrows show STAT6 (a) and p-STAT6 (b) (100120 kDa). Data are representative of three differ- ent experiments.

Article Snippet: Neutralization with anti-interleukin-13Ra1 and antiinterleukin-13Ra2 antibodies during interleukin-13 incubation To examine the blocking effect of anti-IL-13Ra1 and antiIL-13Ra2 antibodies on goblet cell hyperplasia and MUC5AC expression induced by IL-13, NHBECs were incubated with IL-13 (10 ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL, R&D Systems Inc., Minneapolis, MN, USA), anti-IL-13Ra2 antibody (2.5 mg/mL, R&D Systems Inc.) or a vehicle (PBS) for 7 or 14 days.

Techniques: Western Blot, Incubation, Recombinant

Journal: Genes & Diseases

Article Title: IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53

doi: 10.1016/j.gendis.2023.01.027

Figure Lengend Snippet: IL-13 promotes the stemness and autophagy of CRC-CSCs by regulating the K48-linked ubiquitination of p53. (A) The correlation between p53 signaling pathway gene sets and rIL-13 treatment is assessed via GSEA. (B) The mRNA and protein level of p53 in HCT116 cells treated with different concentrations of rIL-13. (C, D) HEK293T cells were first transfected with HA-p53 vector and then treated with rIL-13 or PBS. The cell lysates were subjected to an IP assay with anti-HA agarose and immunoblotted with ubiquitin and K48-ubiqutin antibodies. (E, F) HEK293T cells were first transfected with HA-p53 vector and then cotransfected with UBE3C siRNA. The cell lysates were subjected to an IP assay with anti-HA agarose and immunoblotted with ubiquitin and K48-ubiqutin antibodies. (G) Interaction between UBE3C and p53 was assessed upon IL-13 stimulation using Co-IP analysis. (H, I) Colony formation was assessed after transfection of UBE3C siRNA in IL-13-treated HCT116 cells. (J, K) Cell migratory ability was analyzed after transfection of UBE3C siRNA in IL-13-treated HCT116 cells. (L, M) Spheroid-forming ability was assessed after transfection of UBE3C siRNA in IL-13-treated HCT116 cells. Student's t -test (two-tailed) was used for I, K & M. Data are presented as the mean ± SEM of three independent experiments.

Article Snippet: The siRNAs targeting IL-13RA2 and UBE3C and the scrambled control siRNA (NC) were purchased from RiboBio (Shanghai, China).

Techniques: Ubiquitin Proteomics, Transfection, Plasmid Preparation, Co-Immunoprecipitation Assay, Two Tailed Test

Journal: Genes & Diseases

Article Title: IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53

doi: 10.1016/j.gendis.2023.01.027

Figure Lengend Snippet: IL-13RA2 is a molecular link between UBE3C and p53. (A) The protein level of IL-13RA2 was assayed in HCT116 cells treated with different concentrations of rIL-13. (B, C) HEK293T cells were first transfected with HA-p53 vector, and the cells were cotransfected with IL-13RA2 siRNA. The cell lysates were subjected to an IP assay with anti-HA agarose and immunoblotted with ubiquitin and K48-ubiqutin antibodies. (D) HEK293T cells were cotransfected with HA-p53 vector and IL-13RA2 siRNA. The interaction between UBE3C and p53 was assessed by Co-IP analysis. (E) HEK293T cells were cotransfected with HA-p53 vector and UBE3C siRNA. The interaction between IL-13RA2 and p53 was assessed by Co-IP analysis. (F) HEK293T cells were cotransfected with HA-p53 vector and gradient IL-13RA2 plasmids. The cell lysates were subjected to an IP assay with anti-HA agarose and immunoblotted with the K48-ubiqutin antibody. (G) HEK293T cells were cotransfected with HA-p53 vector and gradient IL-13RA2 plasmids. The interaction between UBE3C and p53 was assessed using Co-IP analyses.

Article Snippet: The siRNAs targeting IL-13RA2 and UBE3C and the scrambled control siRNA (NC) were purchased from RiboBio (Shanghai, China).

Techniques: Transfection, Plasmid Preparation, Ubiquitin Proteomics, Co-Immunoprecipitation Assay

Journal: Genes & Diseases

Article Title: IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53

doi: 10.1016/j.gendis.2023.01.027

Figure Lengend Snippet: Schematic diagram of the study. IL-13 promotes IL-13RA2 expression and activation. Then, activated IL-13RA2 mediates and enhances the interaction of the E3 ubiquitinase UBE3C and the substrate p53 protein, resulting in p53 ubiquitination. p53 ubiquitination activates autophagy, which ultimately promotes the self-renewal and tumorigenesis of CRC-CSCs.

Article Snippet: The siRNAs targeting IL-13RA2 and UBE3C and the scrambled control siRNA (NC) were purchased from RiboBio (Shanghai, China).

Techniques: Expressing, Activation Assay, Ubiquitin Proteomics

Journal: Breast Cancer Research : BCR

Article Title: Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate

doi: 10.1186/s13058-025-02100-y

Figure Lengend Snippet: Gene expression of the four target receptors . A Heatmap of gene expression of epha2, epha3, ephb2 and il-13ra2 in TCGA breast cancer data set. The data for all types and triple negative and HER2 negative breast cancer are presented. The results shown here are in whole or part based upon data generated by the TCGA Research Network ( https://www.cancer.gov/tcga ). B Breast carcinoma TMA containing single core per case. Staining for the target receptors included 50 cases of primary breast cancer with 46 cases of invasive carcinoma of no special type, 1 neuroendocrine carcinoma, and 3 medullary carcinomas. Tissue was scored for staining intensity by a neuropathologist at AHWFB (Dr. Ryan T. Mott) on a scale of 0–3 (see also Additional File 5 A). C Lymph nodes TMA containing single core per case. Score is 0 to 1 +, HER2-negative; score 2 +, borderline or equivocal; score 3 +, HER2-positive

Article Snippet: Primary antibodies included EphA2 (clone D7 purified in house), EphA3 (MyBiosource, San Diego, CA, cat# MBS821916), EphB2 (R&D Systems, Minneapolis, MN, cat# AF467), IL-13RA2 (HUABIO Woburn Massachusetts cat# HA722051), PLK-1 antibody 1:1000 (Genetex, cat# GTX15779 Irvine, CA), and Her2 1:1000 (Cell Signaling, cat# 4290 Danvers, MA).

Techniques: Gene Expression, Generated, Staining

Journal: Breast Cancer Research : BCR

Article Title: Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate

doi: 10.1186/s13058-025-02100-y

Figure Lengend Snippet: A SDS-PAGE of QUAD (lane 1) and its QUAD-DM1 conjugate (lane 2). B Cell viability assay of QUAD-DM1 conjugate on five breast cancer cell lines, including a pair of primary and metastatic tumors (MDA-MB-231 and MDA-MB-231-BrM). The IC 50 s of QUAD-DM1 for the cell killing is shown in the accompanying table. One breast cancer cell line, the BT549 cells, was less responsive to QUAD-DM1. These cells do not express QUAD receptors (not shown), and any cytotoxicity observed is likely dependent on the action of DM1 rather than through targeting by the QUAD ligand. C Western blot analysis of target receptors in established breast cancer cell lines. Primary antibodies included EphA3 (MyBiosource), EphA2 (clone D7 made in house), EphB2 (R&D Systems) and IL-13RA2 (HUABIO). Molecular weights of the proteins are as follows: EphA3, 110,131 Da; EphA2, 108,266 Da; EphB2, 117,493 Da; and IL-13RA2, 44,176 Da. All four proteins are glycosylated hence molecular weights in Western blots are higher than predicted from the primary sequence. D Flow cytometry for QUAD in human breast cancer cell lines. The red line corresponds to QUAD and the black line represents isotype control. E QUAD-DM1 causes cell cycle arrest in G2 phase. Data was analyzed with FCS Express using multicycle DNA analysis. F Cellular events in response to QUAD-DM1. QUAD-DM1 caused sustained histone H3 Ser-10 phopshorylation, Aurora A expression and PLK-1 expression

Article Snippet: Primary antibodies included EphA2 (clone D7 purified in house), EphA3 (MyBiosource, San Diego, CA, cat# MBS821916), EphB2 (R&D Systems, Minneapolis, MN, cat# AF467), IL-13RA2 (HUABIO Woburn Massachusetts cat# HA722051), PLK-1 antibody 1:1000 (Genetex, cat# GTX15779 Irvine, CA), and Her2 1:1000 (Cell Signaling, cat# 4290 Danvers, MA).

Techniques: SDS Page, Viability Assay, Western Blot, Sequencing, Flow Cytometry, Control, Expressing

Journal: Breast Cancer Research : BCR

Article Title: Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate

doi: 10.1186/s13058-025-02100-y

Figure Lengend Snippet: Expression of the four target receptors in breast cancer primary tumors and breast cancer metastases to brain ( A ). Control staining is shown in Additional File 4. B Immunohistochemistry of breast cancer metastases to brain. Commercial TMA of multiple metastases to brain: 5 patients/2 cores per patient samples. C Histological scoring of IL-13RA2. EphA3, EphA2, and EphB2 staining of ten patient-matched breast cancer and its brain metastasis). Estrogen receptor (ER), progesterone receptor (PR) and HER2 scoring of the samples were obtained from patients’ original pathology report following surgery, neurological symptoms or IHC changes. All tissue samples were collected at AHWFB-CCC Tissue Bank

Article Snippet: Primary antibodies included EphA2 (clone D7 purified in house), EphA3 (MyBiosource, San Diego, CA, cat# MBS821916), EphB2 (R&D Systems, Minneapolis, MN, cat# AF467), IL-13RA2 (HUABIO Woburn Massachusetts cat# HA722051), PLK-1 antibody 1:1000 (Genetex, cat# GTX15779 Irvine, CA), and Her2 1:1000 (Cell Signaling, cat# 4290 Danvers, MA).

Techniques: Expressing, Control, Staining, Immunohistochemistry

Journal: Breast Cancer Research : BCR

Article Title: Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate

doi: 10.1186/s13058-025-02100-y

Figure Lengend Snippet: Immunoreactive EphA2, EphA3 and IL-13RA2 in brain metastatic breast cancer. Complementary and overlapping expression of EphA2, EphA3 and IL-13RA2 in breast metastatic cancer by immunofluorescence. Almost all cells stained for one of the tested three receptors. BTCOE 5391 is HER2 + and BTCOE 5542 represents TNBC

Article Snippet: Primary antibodies included EphA2 (clone D7 purified in house), EphA3 (MyBiosource, San Diego, CA, cat# MBS821916), EphB2 (R&D Systems, Minneapolis, MN, cat# AF467), IL-13RA2 (HUABIO Woburn Massachusetts cat# HA722051), PLK-1 antibody 1:1000 (Genetex, cat# GTX15779 Irvine, CA), and Her2 1:1000 (Cell Signaling, cat# 4290 Danvers, MA).

Techniques: Expressing, Immunofluorescence, Staining